TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06239194: Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Sponsor: ModeX Therapeutics, An OPKO Health Company · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 330 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06239194 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06239194 Rescue Dossier →